Gilead Sciences stock has delivered very strong long term returns over the past five years, yet current valuation checks and market multiples still point to the shares screening as undervalued. With recent news flow focused on its HIV and oncology franchises and on legal protection of its U.S. drug pricing, investors are weighing how much of this is already reflected in the price.

• Gilead Sciences has returned 148.1% over the past five years, which puts recent valuation questions in the context of a stock that has already created substantial shareholder value.
• Progress in oncology and HIV treatments alongside partnerships in areas like tissue analytics can support confidence in future cash flows, while ongoing legal and regulatory risks around drug pricing and supply channels may limit how much investors are willing to pay for that growth.
• The broader valuation checks lean cheap, with Gilead Sciences screening as undervalued on 5 of 6 measures on Simply Wall St's valuation framework.

The issue now is whether Gilead Sciences' current share price still leaves enough upside relative to what these valuation checks suggest.

Is Gilead Sciences a Bargain on Sales?

The price-to-sales (P/S) multiple suits Gilead Sciences because revenue is a key anchor for valuing large biopharma companies with established product franchises.

Gilead Sciences trades on a P/S of 6.0x. This compares with an industry average of 11.6x for biotechs and a peer group average of 7.5x. The fair P/S ratio implied by Simply Wall St's model is 9.9x, which reflects what investors might be expected to pay for Gilead Sciences given its margins, scale and risk profile.

On that basis, the stock changes hands at a sizeable discount to the modelled fair P/S, even after recent headlines around its HIV and oncology pipeline and a legal win on HIV drug imports. The gap suggests the market is pricing Gilead Sciences below what these revenue-based checks imply.

On the P/S multiple, Gilead Sciences stock appears undervalued relative to both its fair ratio and sector benchmarks.

The Gilead Sciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Gilead Sciences valuation puzzle leaves off and spell out what growth, margin and earnings outcomes would need to hold for the stock to be worth materially more or less than today. Each one treats Gilead Sciences' fair value as a thesis about the business that you can watch over time, and they sit on Simply Wall St's Community page for investors who want to follow those stories.

Community narratives on Gilead Sciences stock pull in opposite directions, with one cohort seeing clear valuation upside and another warning on execution and pricing risk.

Bull case: 18% undervalued

"Gilead’s upcoming launches, including twice-yearly lenacapavir for PrEP, anito-cel cell therapy for multiple myeloma, and Trodelvy’s move into first-line triple-negative breast cancer, positively position the company to capture significantly larger addressable markets…"

Bear case: 15% overvalued

"Bear case: Execution risk (M&A integration, oncology competition, pricing pressure) and near-term EPS dilution."

Do you think there's more to the story for Gilead Sciences? Head over to our Community to see what others are saying!

The Bottom Line

Gilead Sciences screens as undervalued on market multiples, which points to a discount that investors may consider significant. The key question is whether that gap reflects genuine mispricing or a sensible cushion for execution and pricing risk around its HIV and oncology franchises. From here, the call depends on whether Gilead Sciences can deliver on its product pipeline and manage regulatory and legal pressures in a way that prompts the market to reconsider how much it is willing to pay for those cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.